Deals

News Photos

Amgen drug shrinks tumors in lung cancer patients with KRAS gene mutation - study
Click on the image below to view in Stereo 3D

Amgen drug shrinks tumors in lung cancer patients with KRAS gene mutation - study
The median length of time that patients given the drug sotorasib lived before their disease worsened was 6.3 months for lung cancer patients and 4 months for colorectal cancer patients, the company said. Patients in the Phase I trial involving several types of cancer were treated with once daily sotorasib. The oral medication is designed to target a mutated form of a gene known as KRAS that occurs in about 13% of non-small cell lung cancers (NSCLC), the most common type of lung cancer.
More Description
Image URL

 
 
 
vlrPhone
vlrFilter
vlrMemos

Project of very low consumption, radiation and bitrate softphones
Multifunction Audio Filter with Remote Control
App to measure the quality of the voice
More Information
Free the Animation VR
AR

Play to reveal 3D images and 3D models
More Information

WhmSoft Moblog
Copyright (C) 2006-2020 WhmSoft
All Rights Reserved